Dr. Chad Schmiedt performs surgery at the University of Georgia Veterinary Teaching Hospital. — ABC News
(ATHENS, Ga.) — Some cats battling kidney disease are getting a second chance at life, thanks to a pioneering kidney transplant program at the University of Georgia Veterinary Teaching Hospital.
Dr. Chad Schmiedt leads the initiative and is one of only a handful of surgeons who performs the procedure around the world.
“One particular thing about cats is that they are so good at hiding their disease. So, a lot of times, cats won’t start showing signs of illness and owners won’t pick up on signs of illness until it’s quite advanced,” Schmiedt told ABC News Live. “And so that’s one challenge we face in these animals, is trying to work with those very sick animals.”
It’s a type of advanced veterinary care growing in demand as pet ownership has surged over the last 30 years. As of 2023, 66% of U.S. households — 86.9 million homes — own a pet, according to the American Pet Products Association’s [APPA] annual survey. Millennials make up the largest percentage of current pet owners at 33%.
Around three-quarters of cat owners said they considered their pets to be a member of the family, according to the American Veterinary Medical Association’s 2018 and 2022 report on U.S. pet ownership, and that could lead to increased expenses for their care. Just last year, Americans spent $136.8 billion on their pets, the APPA survey said.
“It’s considered absolutely normal behavior for people to love their animals, spend whatever it takes to fix their animals when they get sick. You have to go back to the fact that for many people, these animals are like their kids,” said Dr. James A. Serpell, professor of ethics and animal welfare at the University of Pennsylvania School of Veterinary Medicine.
That was the case five years ago for Franklin, Tennessee, resident Greg Norwicki, whose beloved cat Tucker was diagnosed with kidney failure after routine blood work showed slightly elevated creatinine and blood urea nitrogen – indicators for kidney disease. Tucker’s levels continued to rise over the following months, then Norwicki learned Tucker may be a candidate for a kidney transplant.
The transplant was a success, and Tucker is still alive — and thriving.
“We don’t realize how sick our animals are until you see an animal bounce back,” Norwicki said.
At the University of Georgia, the surgery costs around $20,000 for both the recipient and donor cat, Schmiedt said. There are also recurrent costs — it’s estimated owners can expect to spend anywhere between $1,500 to $4,000 per year on medication, tests and veterinary visits.
Donor cats come from a variety of places, including other cats owned by the family of the recipient. The donor cats are always adopted by the family of the recipient, Schmiedt said.
“To the best of our knowledge, they go on and live a normal life,” Schmiedt said.
Still, some have raised ethical concerns about the program, arguing that unlike humans, cats can’t give consent to have their organs donated.
“Those donor cats don’t come along and say, ‘Yes, please take my kidney.’ The argument that is used is that most of those donor cats are coming from shelters. They might not have found a home. They might have been euthanized in the shelter. So donating a kidney to another cat is preferable to that, especially if the recipient household of that new kidney is willing to adopt the donor,” Serpell said.
In Norwicki’s case, Charlie, the donor cat for Tucker, was previously used for research and was adopted by the family after the procedure.
“So as I say, you know, we saved [Charlie’s] life, too,” Norwicki said.
(NEW YORK) — Wildfires across the United States and Canada — fueled by record heat and dry conditions — could severely impact the health of millions of people.
Smoke from wildfires in several Canadian provinces, including Ontario, Quebec and Nova Scotia, led to air quality alerts throughout several states in the Midwest, mid-Atlantic and Northeast. Additionally, fires in Michigan and New Jersey have created dense fog and heavy smoke.
Inhaling toxic smoke and ash from wildfires could cause damage to the body — including the lungs and heart — and even weaken our immune systems, experts said.
“Wildfire smoke itself is quite a complex mixture and it’s made up of fine particles … and a number of other gases, which are toxic, mainly due to the fact that wildfires burn everything so more toxic than household fires because everything has been burned,” Dr. Kimberly Humphrey, a climate change and human health fellow at the Center for Climate, Health, and the Global Environment at Harvard T.H. Chan School of Public Health, told ABC News.
Fine particulate matter known as PM2.5, which is 30 times smaller in diameter than a human hair, is of particular concern.
Because these particles are too small to be seen with the naked eye, they can easily enter the nose and throat and can travel to the lungs, with some of the smallest particles even circulating in the bloodstream, according to the Environmental Protection Agency.
“The top offender here is these fine particles,” Dr. Vijay Limaye, a climate and health scientist at the National Resources Defense Council, told ABC News. “That size is really important because can penetrate really deeply and wreak havoc on the body.”
PM2.5 can cause both short-term health effects, even for healthy people, including irritation of the eyes, nose and throat; coughing, sneezing; and shortness of breath and long-term effects such as worsening of conditions such as asthma and heart disease.
This is especially concerning for vulnerable groups including children, pregnant people, older adults and those who are immunocompromised or having pre-existing conditions.
“Lower socioeconomic neighborhoods are at a higher risk as well,” Humphrey said. “Often they don’t have the ability for financial reasons, predominantly, and also social reasons to get away from wildfire smoke, they may not be able to shelter inside, they may not be able to afford the equipment to protect their lungs from the smoke.”
Not all PM2.5 particles are the same. One study from California in 2021 found that those from wildfires can be up to 10 times more harmful than the same type of air pollution coming from combustion activity.
Being exposed to smoke can cause lung inflammation and could make it harder to remove inhaled foreign materials and bacteria, potentially increasing the susceptibility to respiratory infections, including COVID-19, according to the Centers for Disease Control and Prevention.
Depending upon the length and amount of exposure, prolonged lung inflammation could result in impaired lung function that lasts long after the wildfire has ended.
Additionally, studies have shown a link between poor air quality — which these fires have caused — and cardiovascular disease, including strokes, heart attacks, heart failure and atrial fibrillation.
Because of climate change, there will not only be more record-setting wildfires but also more people at risk of inhaling toxic smoke as well, the experts said.
“It’s clear that the climate change problem is essentially creating conditions that make the fire problem and the smoke problem worse,” Limaye said. “So, we’re talking about, hotter days, longer wildfire, seasons, drier conditions, spring snowmelt that essentially, put more wildfire fuel in play earlier — all these kinds of converging factors.”
He added, “And I think it’s reasonable to expect that wildfire smoke is going to grow as a public health concern in the coming years.”
Humphrey recommends that people stay aware of their local air quality and, if it reaches unhealthy levels, to wear a mask, ideally an N95.
(NEW YORK) — As the popularity of drugs like Wegovy and Ozempic used for weight loss continues to rise, another weight loss-focused company is jumping into the market.
Noom, an app that helps people track their eating and exercise habits, will now offer prescriptions through a new telehealth platform known as Noom Med.
The company said Noom Med will be available to people who meet certain requirements — such as a BMI of 30 or higher — and who are members of Noom Weight, its $42 per month program that offers psychological tips to help with weight loss.
The cost of Noom Med will be $49 per month and includes “interactive patient education, a psychologically-aware curriculum, and a suite of comprehensive nutrition & exercise tools,” according to the company.
Users who qualify can be prescribed weight loss medications after undergoing “comprehensive lab work” and a “health evaluation by a board-certified physician or a physician-supervised nurse,” according to Noom.
Noom’s entry into the medication market comes three months after WW, formerly known as Weight Watchers, made the same move.
In March, WW announced it had acquired Sequence, a subscription-based telehealth platform that provides telemedicine appointments with doctors who can prescribe popular medications like Ozempic and Wegovy.
“These companies are profit-driven,” Maya Feller, a New York-based registered dietitian nutritionist, told ABC News’ Good Morning America. “And if people want to lose weight and they center that as the thing that’s valuable, we’re going to see more companies jump on the bandwagon and start to use these GLP-1s.”
Ozempic and Wegovy are part of a class of drugs called GLP-1 RAs that help people produce insulin and lower the amount of sugar in the blood. The drugs slow down movement of food through the stomach, curbing appetite and leading to weight loss.
Both drugs are made from a compound called semaglutide, which works by helping the pancreas release insulin to move sugar from the blood into body tissues.
A third popular drug now being used for weight loss is Mounjaro, whose active ingredient, tirzepatide, works by activating two naturally produced hormones in the body: glucagon-like peptide-1, known as GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP.
The combination is said to slow the emptying of the stomach by making people feel full longer, suppress appetite by slowing hunger signals to the brain, and help reduce blood sugar.
Mounjaro is currently approved by the U.S. Food and Drug Administration to treat Type 2 diabetes. The drug’s maker, Eli Lilly, announced in April that it expects an additional version of the medication could be approved by the FDA for weight loss as early as the end of the year.
The FDA approved Ozempic in 2017 as a treatment for Type 2 diabetes alongside diet and exercise if other medications cannot control blood sugar levels well enough. Although Ozempic is not explicitly approved for chronic weight management, it can be prescribed off-label and used for people who are obese.
Wegovy is essentially the same injectable drug as Ozempic, prescribed at a higher dosage. The FDA has specifically approved Wegovy for patients with severe obesity, or who are overweight and have one or more weight-associated conditions like high blood pressure or high cholesterol.
Without insurance coverage, the cost of the medications can run over $1,000 per month.
“What I’ve seen when patients are on these medications is that it drastically changes their relationship with food, so this idea that this is an easy fix is completely not true,” Feller said. “There are tons of side effects that go on with this medication, and people are actually sacrificing quite a bit to have thinness and live in a smaller body.”
Ozempic, Mounjaro and similar medications cannot be given to patients with certain medical conditions, including medullary thyroid cancer, pancreatitis or gallstones.
Side effects of the medications can include severe nausea and constipation.
Tiffany Groves, of Texas, says taking the drug Mounjaro has improved her PCOS and helped her lose weight. — Courtesy Tiffany Groves
(NEW YORK) — Branneisha Cooper of Texas said she was diagnosed during her senior year of high school with polycystic ovary syndrome, or PCOS, a reproductive hormone imbalance that can cause problems with the menstrual cycle and lead to the formation of multiple ovarian cysts and infertility, according to the U.S. Office on Women’s Health.
The exact cause of PCOS is unknown, but people with this condition have higher levels of androgens, such as testosterone, and insulin that can lead to insulin resistance which is a risk factor for Type 2 diabetes.
Cooper, now 26, said she suffered for over a decade with irregular menstrual cycles, hormonal imbalances and weight gain.
That changed late last year, she said, when her doctor prescribed her Mounjaro, an injectable medication approved by the Food and Drug Administration in May 2022 to treat Type 2 diabetes.
“[My doctor] said, ‘There’s this great medication and I have a couple of women on it already who also have PCOS,'” Cooper told “Good Morning America,” adding, “Since starting on Mounjaro, it has honestly just been like a stress relief. I feel like a weight has been lifted off my shoulders.”
Since starting on the medication in November, Cooper said she has had a menstrual cycle regularly each month, has experienced reduced inflammation and has lost over 40 pounds.
She said she is also thinking, for the first time since her diagnosis, about becoming pregnant in the future, something she said she was previously told was unlikely to happen.
“For me especially, since I’m taking this for PCOS, this is so much more than weight loss for me, Cooper said. “Now that my cycles are regular again and I’m ovulating, it’s like I can think again about that thought I’d pushed back in my mind, of being a mom.”
Cooper is among a growing number of women with PCOS who are turning to medications like Mounjaro and Ozempic to treat their condition. The medications have been in the headlines recently for their growing popularity as drugs used for weight loss.
Like Mounjaro, Ozempic is approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication “off-label” for weight loss, as is permissible by the FDA.
Many women, including Cooper, are talking about the medications on social media, where they say they’re finding a community of women who have long struggled with PCOS and struggled to find any medications to ease their symptoms.
Symptoms of PCOS can include everything from irregular or absent periods to excessive facial hair, acne and obesity. The exact cause of PCOS is not known.
The condition affects 1 in 10 women of childbearing age, according to the Office on Women’s Health.
“Prior to being on this medication, I thought it was just a me problem, that there was just something that I wasn’t getting right that other people were,” Cooper said. “It wasn’t until I [went] on Mounjaro and realized it’s a chronic disease … and you weren’t the problem.”
Tiffany Groves, who also lives in Texas, said she too struggled with PCOS for nearly a decade before going on Mounjaro last October, after learning about the medication on TikTok.
She was prescribed the medication off-label to help treat PCOS, and said she has since experienced regular menstrual cycles for the first time in her life. The 38-year-old said she has also lost around 43 pounds.
“This whole time I’ve been living life and thinking it’s normal to think about food all the time and then all of a sudden, you don’t think about food,” Groves told “GMA” of her experience on Mounjaro. “I can just eat a little bit and be perfectly fine.”
How drugs like Ozempic, Mounjaro can help PCOS
Typically, treatment options to manage PCOS symptoms include hormonal birth control and anti-androgen medicines as well as weight loss, according to the Office on Women’s Health.
Dr. Rekha Kumar, an endocrinologist at Weill Cornell Medicine and NewYork-Presbyterian and an expert in obesity and PCOS, said that drugs like Ozempic and Mounjaro can be helpful in treating the condition because they help address one of its main underlying problems, insulin resistance.
“It’s not necessarily that we’re using the meds to treat PCOS, but the meds can be helpful for one of the symptoms of PCOS, which is the actual weight gain and hormonal drive to eat carbohydrate because of the insulin resistance,” Kumar said, adding, “What we’ve learned in the past 20 years is that PCOS is actually an insulin-carbohydrate-metabolism problem called insulin resistance, meaning the body makes more insulin in response to carbohydrates.”
She continued, “And what people often forget about insulin is that it’s a fat storage-promoting hormone, so the more insulin your body is making, the better you are at storing fat.”
The active ingredient in Mounjaro, tirzepatide, works by activating two naturally produced hormones in the body: glucagon-like peptide-1, known as GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP.
The combination is said to slow the emptying of the stomach by making people feel full longer, suppress appetite by slowing hunger signals to the brain, and help reduce blood sugar.
Ozempic is made from a compound called semaglutide, which works by helping the pancreas release insulin to move sugar from the blood into body tissues.
It also works by slowing down movement of food through the stomach and curbing appetite, thereby causing weight loss.
Ozempic and Mounjaro cannot be given to patients with certain medical conditions, including medullary thyroid cancer, pancreatitis or gallstones. Side effects of the medications can include severe nausea and constipation.
Kumar said she has been prescribing this class of medications to patients with PCOS for over a decade, saying, “The people that really know the science about how these medicines work as well as the science of PCOS have understood the link for some time.”
Kumar noted that as drugs like Ozempic and Wegovy have risen in popularity in recent months, she has found it harder to get her prescriptions for patients approved by insurance.
Both Ozempic and Wegovy are considered off-label for PCOS. Without insurance coverage, the cost of the medications can run over $1,000 per month.
“We used to be able to prescribe these a little easier, before the Ozempic craze,” Kumar said. “Because now there’s so much inappropriate prescribing that even the one-off cases that might do really well on these medicines are getting denied because there’s so much scrutiny on each prescription.”
Kumar and other doctors say that patients having a hard time accessing Ozempic or Mounjaro due to shortages or insurance problems should speak to their doctor about alternative options within the same class of medications.
Because PCOS is many times diagnosed in women as they are experiencing fertility struggles, Kumar said it’s also important for women to know that medications like Ozempic and Mounjaro should not be taken during pregnancy or while trying to become pregnant.
“We just have to really make sure that patients understand the risks and the unknowns of getting pregnant on these medicines, because when we do treat people’s insulin resistance, they become more fertile,” Kumar said. “Women who thought that they could never get pregnant, if you’re treating them with these medicines, they might, so we just have to be very careful with educating on the risks.”
The FDA also says in its safety profiles of these drugs that they should not be taken during pregnancy, noting there is “insufficient data” available.
The FDA also explains that the drugs could cause weight loss, and that “weight loss offers no benefit to a pregnant patient and may cause fetal harm.”
The FDA recommends that people discontinue treatment at least two months before they plan to become pregnant.
Both Cooper and Groves said they have plans in place with their doctors to go off Mounjaro if they ever try to become pregnant in the future. Cooper said she anticipates being on Mounjaro “long-term” for PCOS, except for when she tries to have a child.
“It’s treating my PCOS — it’s not curing it, it’s treating it,” Cooper said. “And this is the best I’ve felt my entire adult life.”
(NEW YORK) — COVID-19 cases may be increasing again in New York City, new wastewater data hints.
Nearly all of the 14 wastewater treatments plants in the city are currently in the “high” detection level category, meaning likely 50 or more cases per 100,000 people, according to the NYS Wastewater Surveillance Network dashboard, which was updated Friday.
What’s more, two-week trend data shows that just three of the plants are seeing decreases in virus detection.
Reported case numbers have not jumped. But fewer people are getting tested than earlier in the pandemic, so case numbers are a less reliable indicator of COVID-19 spread.
Health experts told ABC News that wastewater tracking is a good early detection tool for monitoring potential future upticks, but it’s too early to determine what it means.
“Wastewater data can be a very helpful indicator of what is taking place,” said Dr. John Brownstein, an epidemiologist and chief innovation office at Boston Children’s Hospital and an ABC News contributor. “Now, it’s an indication of the level of virus that people might be shedding, but it’s not 100% related to the amount of illness people are experiencing.”
He continued, “Because with the significant amount of immunity from previous infections, from vaccination, there may be community transmission, but it may be asymptomatic and so what wastewater can’t tell you is actually the severity of the cases in the community.”‘
Wastewater surveillance checks for the virus in sewage — from households and buildings — that contains human fecal matter.
Because at least half of COVID-19 patients shed genetic material from the virus, or viral RNA, in their feces, the same tests that can determine if someone is positive can also detect the virus in wastewater samples.
When people shed the virus in their stool, they are often in the early stages of the infection, meanings levels of the virus in wastewater samples will often occur before the number of cases rise.
Reported COVID-19 cases have remained relatively flat since mid-April at about 270 cases for a seven-day rolling average, according to data from the city’s Department of Health and Mental Hygiene. Hospitalizations and deaths have also remained relatively flat.
“Wastewater data is…unbiased,” Dr. Peter Chin-Hong, an infectious diseases specialist at the University of California, San Francisco, told ABC News. “It just depends on the amount of virus circulating in the community, so although the absolute number might be debatable, that trend is always something that makes us pay attention.”
However, he cautioned not to panic and said just because there are areas of the city in the “high” category, that does not mean a surge is imminent.
While the end of mitigation measures such as masking and some waning immunity may play a role if cases increase, Chin-Hong said the U.S. is in a much better position than it was in years past.
“In the old days, we just kind of had to be subject to the whims of the virus, but now we have weapons to fight back,” he said. “And even if vulnerable populations are infected, they could avert or prevent hospitalization and death by taking advantage of these early, antivirals taken early in the course of disease, like Paxlovid and remdesivir and molnupiravir.”
The experts said it’s natural that wastewater data is going to ebb and flow and it is not going to stay low all the time. However, because everyone has a different risk tolerance, the data can help people decide if they want to modify their behavior.
“Knowing that viruses circulating may inform people about the kinds of activities you want to take part in,” Brownstein said. “So just like you bring an umbrella for rain, you may change your behavior if you know that viruses are circulating. This is not a reason to panic. But more information can help empower people to make their own decisions.”
(NEW YORK) — A breast cancer drug already on the market has been found to lower the chances of breast cancer recurring, an advancement that could open the drug to a broader range of patients.
The pharmaceutical company Novartis announced the findings Friday about its breast cancer treatment Kisqali, a drug already approved by the U.S. Food and Drug Administration for people with more advanced stages of breast cancer.
The vast majority of breast cancer patients are diagnosed in the early stages of disease. Right now, many are treated with chemotherapy and endocrine therapy.
The new data shows that adding Kisqali after primary treatment will reduce the risk of the cancer coming back.
This finding could be good news specifically for women who are diagnosed in the earlier stages of the disease and those who are hormone-receptor positive, and HER2 negative, who make up 70% of the breast cancer population, according to the National Cancer Institute.
“Women who have this subtype can have recurrences even 20 to 25 years after their initial diagnosis,” Dr. Dennis Slamon, director of the Revlon/UCLA Women’s Cancer Research Program and lead investigator of the Kisqali clinical trial, told ” Good Morning America.” “We found that adding this drug to the best available standard therapy will decrease the recurrence rate by as much as 25%.”
Suzanne Garner, 45, participated in the clinical trial for Kisqali after being diagnosed with Stage 2 cancer five years ago.
She said she was treated with chemotherapy and endocrine therapy, but the potential outcome of the treatments “didn’t feel right.”
“I felt that my risk of recurrence was still too high,” Garner told “GMA.” “I have a young daughter who needs her mom around for as long as possible and I would absolutely do anything to reduce my risk of recurrence so I can be her mom for as long as she needs me.”
Novartis announced the findings on Kisqali at the 2023 annual meeting of the American Society of Clinical Oncology.
The company said it plans to submit the data to “regulatory authorities in the U.S. and Europe before end of year.”
“Patients diagnosed with HR+/HER2- early breast cancer remain at risk of cancer recurrence, given that one-third of patients diagnosed with stage II and more than half of those diagnosed with stage III will unfortunately experience a return of their cancer,” Dr. Shreeram Aradhye, chief medical officer of Novartis, said in a statement. “The compelling data from NATALEE [the clinical trial] highlight the potential of Kisqali to reduce the risk of cancer recurrence in this at-risk population, including node-negative patients, while maintaining a favorable safety profile. These potentially practice-changing results reinforce the unique and well-established profile of Kisqali as a proven treatment in HR+/HER2- metastatic breast cancer.”
(NEW YORK) — Just six weeks ago, Greg DeStefano began a new chemotherapy combination. The 50-year-old, from Northbrook, Illinois, had recently been diagnosed with his fourth round of cancer and doctors were hopeful the medication would treat the tumors growing in his neck.
DeStefano was responding well, but then, in late May, he got a call from his doctor and was told one of the three drugs he was receiving — carboplatin — was under a global shortage and because of the way the hospital had to prioritize treatments, he wouldn’t be qualified to receive it anymore.
“We’re frustrated because not only are we dealing with cancer, now we have to deal with a drug shortage of a pretty critical drug,” DeStefano told ABC News.
DeStefano’s experience is similar to thousands across the United States of patients either having delayed treatment or being unable to receive treatment because of cancer drug shortages.
Among them are carboplatin, used to treat ovarian and head and neck cancer; azacytidine, which treats a form of leukemia; and dacarbazine, used to treat skin cancer.
“We’ve experienced drug shortages, intermittency, my entire career, it has always been a challenge,” Julie Kennerly-Shah, associate director of pharmacy at The Ohio State University Comprehensive Cancer Center, told ABC News. “The past six months have been the most challenging in my career for managing drug shortages in the cancer population.”
She continued, “As you can imagine, it’s extremely frustrating to know that you have a medication that can potentially cure a patient of cancer or extend their life and to know that you may not have enough to treat that patient.”
Last month, the American Cancer Society issued a warning that chemotherapy drugs had returned to the list of the top-five drug classes affected by shortages and warned this could have a devastating effect on patients.
Some hospitals and clinics are completely out of the medications. In others, doctors are being forced to either ration cancer drugs or triage which patients receive the drugs first.
“We’re sort of on life support, whether or not we’re going to have enough drugs and we have internally operationalized various ways to prioritize who gets which drugs,” Dr. Mark Einstein, a gynecologic oncologist at University Hospital in Newark, New Jersey, told ABC News. “Especially when there are limited or no other alternatives.”
DeStefano said this shortage means that unless he chooses a different course of treatment — which involves chemotherapy and then a resection or a removal of the tumor — he will be ineligible to receive the drug.
However, because he’s had multiple surgeries in the past due to previous bouts of cancer, surgery has more risks for him, his wife, Mindy DeStefano, told ABC News.
“This is the crux of our frustration, that he has a therapy and treatment that’s working and now because of the way they have to categorize and prioritize patients, he is now not able to access this drug any longer,” she said.
Doctors say there are a number of factors behind the nationwide shortage including low profit margins for generic versions of these drugs as well as labor and supply chain issues.
“All these drugs that we have shortages in, they’re all generic, old chemotherapy drugs that are fairly cheap as it relates to cancer drugs,” Dr. Hanna Sanoff, a gastrointestinal medical oncologist at the University of North Carolina’s Lineberger Comprehensive Cancer Center, told ABC News. “And so, the economic margin here is just much smaller for the drug manufacturers.”
She continued, “A lot of our supply comes from India and China, and there have been some recent shutdowns of a couple of major suppliers of generic drugs and so it was already sort of a tenuous supply chain that then got disrupted by plant closures.”
For short-term solutions, the Society of Gynecologic Oncology currently recommends minimizing ordering the drugs under shortage if there is another medication available with comparable efficacy and safety and using the lowest dose possible and the longest interval between doses that is acceptable.
Kennerly-Shah said at her center, patients have either been switched to alternative medications or there have been operational changes.
“Dose rounding is a frequent practice, so rounding to the nearest vial size, within typically a 10% range, so that we’re not wasting additional medication leftover by opening an additional vial,” she said.
For long-term solutions, doctors are calling for more transparency from companies on when additional shipments can be expected, potentially giving incentives for generic drugmakers or even seeing if the FDA can come up with ways to potentially extend the shelf life of critical medications.
Greg DeStefano and Mindy DeStefano said they have potentially found another local hospital in Chicago with supply of carboplatin, but need to have more conversations to see if he qualifies for treatment.
“This is life and death,” she said. “This not like symptom relief; it’s life and death. And it’s really frustrating that in this country, we have to be scrambling to try and find a drug that technically should be available. I mean, it is a life and death drug.”
(NEW YORK) — Teenage birth rates have fallen to their lowest levels ever, new provisional federal data published Thursday found.
The report, from the Centers for Disease Control and Prevention’s National Center for Health Statistics, showed the birth rate among 15- to 19-year-olds in 2022 was 13.5 per 1,000 females.
That’s a 3% drop from the rate of 13.9 per 1,000 in 2021 and a record low in the United States.
Aside from an increase in 2006 and 2007, the teen birth rate in the U.S. has been continuously declining since 1991.
“I’m excited the U.S. has made significant progress in reducing pregnancies among youth,” Dr. Vincent Guilamo-Ramos, dean of the Duke University School of Nursing and whose research interests include teen sexual and reproductive health, told ABC News. “The all-time low should be an indication that we’re continuing to move in the right direction.”
For the report, the authors looked at birth certificate data received and processed by the NCHS.
They found that birth rates declined not just across all teens, but for both younger (ages 15–17) and older (ages 18–19) groups as well.
There was a small drop among 15- to 17-year-olds from 5.6 per 1,000 in 2021 to 5.5 per 1,000 in 2022 but a larger drop among 18- to 19-year-olds from 26.6 per 1,000 to 25.6 per 1,000.
The report did not discuss reasons behind the drop, but experts told ABC News it’s a combination of factors including more teens abstaining from sex, contraceptives becoming more easily available to teens and more pregnancy prevention programs aimed at teenagers.
Dr. Monica Woll Rosen, an assistant professor of obstetrics and gynecology at Michigan Medicine who specializes in pediatric and adolescent gynecology, said there’s also been an increase in popularity among teens for long-acting reversible contraception, like intrauterine devices (IUDs).
“In fact, the American Academy of Pediatrics came out and said that it should be used as first line for birth control,” she told ABC News. “And sort of the marketing around that has caused a lot of teens in this age group to get the IUD and therefore not become pregnant.”
Guilamo-Ramos said these decreases are encouraging to see but said it’s important to keep an eye on the data to make sure birth rates among teens are not slowing down.
“From 2007 to 2021, on average, the sort of reduction in the teen birth rate was about 8%,” he said. “And if you look at the more recent data that was released in the report, it’s 3%. Something kind of to keep an eye on and that it appears like that rate could be slowing down in terms of the progress.”
Rosen added there is more work to be done when it comes to reducing the number of teen pregnancies.
“The number is not zero and teens get pregnant all the time, who may not want to be pregnant but may not be aware of contraceptive options or options for emergency contraception and so [people should] still consider education necessary and at the forefront and the birth rate can still improve even though it’s at an all-time low right now,” she said.
The report also looked at other provisional data and found that overall births did fall to 3,661,220 in 2022 from 3,664,292 in 2021, but it was described by the authors as a nonsignificant decline.
Additionally, the general fertility rate among women aged 15 to 44 declined, but by less than 1% from 56.3 per 1,000 to 56.1 per 1,000.
Among race/ethnicity between 2021 and 2022, the provisional number of births declined 3% for American Indian/Alaska Native and white women and by 1% for Black women from 2021 to 2022.
However, birth rates rose 2% for Asian women and 6% for Native Hawaiian/Pacific Islander and Hispanic women.
The report also focused on pre-term births and found the rate declined 1% in 2022 to 10.38%, from 10.49% in 2021.
Jeffrey Greenberg/Universal Images Group via Getty Images
(NEW YORK) — Digital mental health company BetterHelp is facing multiple potential class action lawsuits over claims from patients that it shared their personal information to advertisers — including Facebook. The lawsuits came soon after BetterHelp agreed in March to pay $7.8 million over charges from the Federal Trade Commission that it revealed sensitive patient data.
“When a person struggling with mental health issues reaches out for help, they do so in a moment of vulnerability and with an expectation that professional counseling services will protect their privacy,” said Samuel Levine, director of the FTC’s Bureau of Consumer Protection, in a statement. “Instead, BetterHelp betrayed consumers’ most personal health information for profit.”
This isn’t the first time a digital mental health service — which could include apps that connect you with a therapist, chatbots, meditation apps, and others — has come under fire for privacy violations. These products market themselves as useful resources for people struggling to navigate mental health care. They’re also more accessible at times than traditional therapists and easier to use from home.
But many of these mental health tools have privacy risks that you won’t find with a traditional, in-person therapist. Mozilla’s Privacy Not Included project says that mental health apps, as a category, have some of the worst privacy protections of any apps on the market.
However, digital mental health tools might still be a good option for some people, but it’s important to check beforehand if you can trust the privacy protections offered by the service you’re using, says Dr. Rebecca Brendel, president of the American Psychiatric Association.
Here are some things to think about when you sign up.
Don’t assume your information will be private
Many digital mental health tools are not governed by the medical privacy law HIPAA. That law protects data collected by health care professionals or hospitals — but not always by apps or websites. An app could, for example, legally share the fact that you signed up for its service with third-party advertisers.
That’s why it’s so important to do your due diligence before using a service, Brendel says. “Entering into mental health treatment is something that’s deeply private and personal for so many of us. And so being sure ahead of time that you can trust that your treatment is actually private and protected is critical,” she says.
Check the privacy policy
Read the privacy policy of any mental health tool closely before you use it, Brendel says. Check if it will be sharing data and what kind of data it will be sharing. Find out if any information will be used for research — either medical research or to improve the app.
“What are some of the guarantees that are being made and what isn’t being made?” she added. Make sure you’re comfortable with the policy, and that you know your rights.
Ask questions during your first visit
People should also ask questions about privacy during their first visit with a provider through the app, Brendel says.
“Asking direct questions at the beginning of a first session is a really important way to ensure that there is integrity in the treatment, and that it protects privacy in a way that makes treatment possible and trustworthy,” she says.
That should include asking if there have been any data breaches at the company, where data is stored, and if there are any reasons to worry about data privacy.
“If there are any red flags or any concerns, it might not be the best option or it might require a little more investigation, Brendel says.
Consider using a virtual service through a hospital rather than a tech company
It can be hard to track down all the information about privacy on an app or website, Brendel notes. If you want to have a higher level of certainty, you may consider accessing a virtual mental health service that’s connected to a hospital or a health care system — rather than a startup or app-based platform.
“Think about systems that really are behind medical firewalls,” she says.
If you’re really worried about privacy, those might be able to give you more peace of mind.
“That can be very, very helpful and reassuring so that you can enter into treatment and focus on getting better and getting the help you need, rather than whether you’re going to be exposed or others are going to find out about it,” Brendel says.
If you are struggling with suicidal thoughts, substance use, or other mental health crises please call or text 988. Trained crisis counselors are available for free, 24 hours a day, seven days a week.
(NEW YORK) — If you’re a female who loves fitness you may have heard the term “cycle syncing,” the idea that you should change up your workouts based on where you are in your menstrual cycle.
The impact of the menstrual cycle in women’s sports has been prominent among professional athletes over the last few years with the U.S. Women’s National Soccer Team tracking their periods ahead of their 2018 World Cup win as a strategy to maximize performance. This year, Orlando Pride, a National Women’s Soccer League team based in Florida, changed their uniforms from white shorts to black shorts to help players feel more “comfortable and confident” while playing on their periods.
Now, curiosity over how the menstrual cycle impacts performance has gone mainstream. The hashtag #cyclesyncing has been used more than 280 million times on TikTok with millions of women sharing how changing their workouts each month based on where they are in their menstrual cycle has benefited their personal health.
Cycle syncing focuses on four main phases of the menstrual cycle: the menstrual phase, follicular phase, ovulatory phase and luteal phase. This training regimen recommends doing different types of workouts for the four different stages of your cycle.
The breakdown of the average cycle syncing training regimen, according to Nike trainer Lauren Schramm, looks like this:
Menstrual phase: Lasts three to seven days. Rest on days one and two of your period, then use optimal movement for when energy levels are low and rest needed is high with activities such as yoga, walking, and barre.
Follicular phase: Lasts around seven days. Focus on speed, power and optimal movement for when energy levels are low to moderate and rest needed is moderate with activities such as heavy lifting, HIIT, boxing, dance and track workouts.
Ovulatory phase: Lasts around three to seven days. Focus on aerobic, endurance and optimal movement for when energy levels are the highest and rest needed is low with activities such as a group fitness classes, long runs, cycling and hot yoga.
Luteal phase: Lasts around seven days. Focus on mobility, recovery and optimal moment for when energy levels are low to moderate and rest needed is moderate to high. Activities can include mobility training, stretching, breath work, yoga and massage.
Does cycle syncing your workouts really help your performance? How can you effectively track your cycle? Is it one size fits all? We asked the experts.
What experts know about cycle syncing
Dr. Ellen Casey, a sports medicine physician from the Department of Physiatry and the Women’s Sports Medicine Center at the Hospital for Special Surgery in New York City, spoke with ABC News’ Good Morning America about her thoughts on the science of cycle syncing.
While your menstrual cycle will impact your physical performance and energy levels, Casey, who has been researching this topic since 2009, says there are benefits for female athletes to track their cycles, but adds there is not enough scientific evidence to show this structured “cycle syncing” method works for everyone.
“I do think it’s very important for female athletes to track their cycles,” Casey says. “It’s when you try to give a sort of group recommendation that I think [is] where we’re falling short to date in the literature, and where I worry that there may be some overselling of cycle tracking and conforming that to your workouts, because we don’t have the data to support that as a group effect at this time.”
Casey said that everyone’s cycle is different — things like the length of phases and estrogen levels vary for every person. This makes it difficult to track the change in phases without using an ovulation stick every morning, which she said can be expensive and time consuming.
“Even if we know exactly that everybody’s on day 10 of their follicular phase, it’s still going to be different, because my level of estrogen might be totally different than yours,” Casey said.
While the cycle syncing method can be used as a baseline, Casey said without proper equipment, like using an ovulation stick each day, there is no sure, scientific way to tell what phase of your cycle your body is in.
“What would be nice is for everybody to be like, ‘Cool, this is where I’m really going to push my strength gains, and this is where I’m going to do endurance work.’ I think at some point you know, when we can check these markers in saliva or whatever … [but] we’re not there yet with the science,” she said.
How tracking your period can influence your workouts
While Casey said the science is not there for a one size fits all cycle syncing program just yet, she does recommend tracking your cycle to figure out how to get best results for yourself.
“I do think there’s value in individual following,” she said.
Referring to cycle syncing, she added, “I think it’s such a fascinating area and I love that people are thinking of it. So, embrace that interest.”
Schramm said she began tracking her cycles when she noticed she wasn’t able to train in the same way and get the same consistent results that her male coworkers and clients were getting.
“I believe cycle-syncing is something that can be taken as far as you desire, and if it’s of interest to begin experimenting with yourself, after clearance from your doctor is obtained, then I think it’s an ideal approach to movement as someone with monthly hormonal fluctuations,” Schramm said.
Schramm said she has seen improvements in her own training by tracking her cycle and following the cycle syncing method of training.
“Understanding the hormonal fluctuations … has clarified why some days I feel my strongest, have unlimited energy and could workout for hours and then the following week, it’s a struggle to get through my warmup,” Schramm said.
Where to start
If you’d like to start monitoring your cycle in relation to your workouts, here several ways you can get started:
Consult with a doctor or trainer: If you are looking to begin a cycle syncing-type process, start by making observations regarding your own menstrual cycle, then consult with a trainer or doctor about the best ways to be active while still respecting your body’s needs for rest and energy.
Track your cycle with apps: Start tracking your cycles. The FitrWoman app, designed by Dr. Georgie Bruinvels, breaks down the four phases of the menstrual cycle and uses evidence-based research to match symptoms and solutions to each phase. This app was used by the U.S. Women’s National Team when training for the World Cup. Other period tracking apps such as MyFlo, Cycles and Period Tracker Lite will help you track your cycle and follow how you feel turning workouts at different points of your cycle.
Use cycle-friendly training tools: More and more fitness brands are adding cycle syncing training as an option in their training programs. Nike has started a “NikeSync” training program with physiologist Stacy Sims, Ph.D., which includes training plans and nutrition suggestions for every phase of the menstrual cycle. Fitness membership program Les Mills + contains a cyclical training guide that includes four workouts to match each week of cycle. Adidas also offer a free “PE(riod)” lesson plan online developed by Buinvels that helps you better understand working out during your menstrual cycle and gives recommendations for each of the four phases.